Clinical Trial Update: Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA) [Phase 3]

View source ↗

Summary

Phase 3 RIO-ASIA trial evaluated the weight-reducing effect and safety of rimonabant in obesity in Asia. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Obesity | Phase 3 | Status: COMPLETED